Johnson & Johnson announced that its Tecnis Eyhance IOL, which the company describes as the first enhanced monofocal IOL, has been implanted in more than 10 million eyes worldwide. “Reaching over 10 million implants is not just a volume milestone—it is validation that Tecnis Eyhance IOL delivers consistent, real-world outcomes at scale,” said Paul Lisenby, Global Head of R&D, Vision at Johnson & Johnson. “That level of adoption reflects years of clinical evidence, surgeon trust, and performance under everyday visual conditions.” Since its global debut in 2019, Tecnis Eyhance IOL is designed to slightly extend depth of focus while maintaining high-quality distance vision and contrast sensitivity under a range of lighting conditions. Built on the long-standing Tecnis platform—used in ophthalmology for more than 25 years—the Eyhance lens is designed to incorporates a continuous power profile to enhance intermediate vision while preserving distance clarity. Clinical studies supporting the lens include: More than 26 studies demonstrating excellent contrast sensitivity, including performance in low-light conditions Over 48 studies highlighting improved intermediate vision outcomes More than 20 studies reporting low incidence of visual disturbances such as halos, glare, and starbursts Tecnis Eyhance IOL is part of Johnson & Johnson’s broader Tecnis portfolio, which combines advanced optical design with proprietary materials. The lineup also includes newer offerings such as the Tecnis PureSee IOL, a purely refractive extended depth of focus (EDOF) lens, and the Tecnis Odyssey IOL, designed to deliver a full visual range. Johnson & Johnson is presenting new clinical data on both Tecnis PureSee and Tecnis Odyssey IOLs at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) 2026 meeting.
